Harnessing the Power of Real-World Data for New Therapies, Upcoming Webinar Hosted by Xtalks

In this free webinar, gain insight into the impact high-quality RWD can play when bringing a new therapy to market. Attendees will learn how to evaluate real-world data (RWD) sources, specifically electronic health record (EHR) data. The featured speakers will discuss methods and opportunities for curating unstructured EHR notes data using AI to support new therapies.

TORONTO, Oct. 28, 2025 /PRNewswire/ — A lack of real-world data (RWD) puts any commercialization strategy on shaky ground. To stay competitive, every pharmaceutical company needs access to high-quality, recent RWD to effectively bring a therapy to market, satisfy postmarketing requirements and track early adoption post-launch. Often, this data is needed before specific J-codes are widely adopted, which leaves critical details in the clinician’s free-hand notes in the electronic health record (EHR).

This webinar will discuss the opportunities in evaluating and leveraging RWD sources, including EHR unstructured clinical notes, to support business decisions surrounding a new therapy launch.

The featured speakers will also explore various methods, including the use of artificial intelligence, by which clinical notes can be curated for use at scale.

This webinar is part of the RWD in Action Series and will feature a discussion that includes:

  1. How high-quality RWD, such as EHR data, can support site selection and patient identification for clinical trials, observational safety and efficacy studies and track real-world usage to inform sales strategies
  2. How to evaluate EHR RWD sources and unstructured note curation
  3. Case studies leveraging EHR RWD for new therapies in thyroid eye disease, etc.

Register for this webinar to learn how real-world data can guide smarter decisions when launching new therapies.

Join Michael Fronstin, Innovator in Life Sciences and Founder, Vireo Strategies LLC; Manfred Stapff, MD, PhD, Founder and Principal, Candid – Advisory Inc; Katherine Vandebelt, CEO, Van de Bytes & Mentor Advisor, PharmStars; Aracelis Torres, PhD, MPH, Senior Vice President of Data & Science, Verana Health, for the live webinar on Thursday, November 13, 2025, at 1pm EST (10am PST).

For more information, or to register for this event, visit Harnessing the Power of Real-World Data for New Therapies.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit www.xtalks.com
For information about hosting a webinar visit www.xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/harnessing-the-power-of-real-world-data-for-new-therapies-upcoming-webinar-hosted-by-xtalks-302596160.html

SOURCE Xtalks

Staff

Recent Posts

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the…

9 hours ago

Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support

LAS VEGAS, Dec. 24, 2025 (GLOBE NEWSWIRE) -- This holiday season, addiction experts at Desert Hope…

9 hours ago

Profound Medical Corp. Announces Upsize of Private Placement

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the…

9 hours ago

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal…

9 hours ago

WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025

Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK)…

9 hours ago